Reporting of Immune Checkpoint Inhibitor Therapy-Associated Diabetes, 2015-2019.
作者信息
Liu Jiaqing, Zhou Huaqiang, Zhang Yaxiong, Fang Wenfeng, Yang Yunpeng, Huang Yan, Zhang Li
机构信息
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China, Guangzhou, China.
出版信息
Diabetes Care. 2020 Jul;43(7):e79-e80. doi: 10.2337/dc20-0459. Epub 2020 May 11.
Abstract
摘要
相似文献
1
Reporting of Immune Checkpoint Inhibitor Therapy-Associated Diabetes, 2015-2019.2015 - 2019年免疫检查点抑制剂治疗相关糖尿病的报告
Diabetes Care. 2020 Jul;43(7):e79-e80. doi: 10.2337/dc20-0459. Epub 2020 May 11.
2
Comment on Wright et al. Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. Diabetes Care 2018;41:e150-e151.对赖特等人的评论。免疫检查点抑制剂相关糖尿病报告增加。《糖尿病护理》2018年；41:e150 - e151。
Diabetes Care. 2019 May;42(5):e77. doi: 10.2337/dc18-2595.
3
Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy.解除制动：一例免疫检查点抑制剂治疗诱发肺动脉高压的病例报告
Pulm Circ. 2020 Nov 11;10(4):2045894020960967. doi: 10.1177/2045894020960967. eCollection 2020 Oct-Dec.
4
Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients.癌症患者接受免疫检查点抑制剂治疗后出现眼外肌增大和甲状腺眼病样眼眶炎症。
Ophthalmic Plast Reconstr Surg. 2019 Jan/Feb;35(1):50-52. doi: 10.1097/IOP.0000000000001161.
5
Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma-An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer.免疫激活与恶性黑色素瘤组织损伤的相关性监测——免疫检查点抑制剂治疗癌症过程中识别耐受崩溃的算法。
Int J Mol Sci. 2020 Mar 16;21(6):2020. doi: 10.3390/ijms21062020.
6
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.外周血 PD1 阳性 CD4 T 淋巴细胞计数可预测接受免疫检查点抑制剂治疗的非小细胞肺癌患者的无进展生存期。
Anticancer Res. 2019 Dec;39(12):6887-6893. doi: 10.21873/anticanres.13908.
7
Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy.免疫介导性小脑炎与免疫检查点抑制剂治疗的关联
Mayo Clin Proc Innov Qual Outcomes. 2018 Feb 1;2(1):74-77. doi: 10.1016/j.mayocpiqo.2017.12.001. eCollection 2018 Mar.
8
Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗的肺癌患者中传染病的新关注点。
Respir Med. 2019 Jan;146:66-70. doi: 10.1016/j.rmed.2018.11.021. Epub 2018 Dec 13.
9
Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.免疫检查点抑制剂（抗CTLA-4、抗PD-1）单药治疗与免疫检查点抑制剂（抗CTLA-4、抗PD-1）联合抗RANKL地诺单抗治疗恶性黑色素瘤的疗效比较：三级医疗中心的回顾性分析
Melanoma Res. 2018 Aug;28(4):341-347. doi: 10.1097/CMR.0000000000000459.
10
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.接受免疫检查点抑制剂治疗的黑色素瘤患者的血小板减少症。
J Immunother Cancer. 2017 Feb 21;5:8. doi: 10.1186/s40425-017-0210-0. eCollection 2017.
引用本文的文献
1
Glycemic management in patients with immune-related diabetes mellitus: A scoping review.免疫相关性糖尿病患者的血糖管理：一项范围综述。
SAGE Open Med. 2025 Jul 29;13:20503121251358313. doi: 10.1177/20503121251358313. eCollection 2025.
2
Durvalumab‑induced type 1 diabetes mellitus in lung adenocarcinoma: A case report and literature review.度伐利尤单抗诱发肺腺癌患者1型糖尿病：一例报告及文献综述
Oncol Lett. 2025 Apr 7;29(6):277. doi: 10.3892/ol.2025.15023. eCollection 2025 Jun.
3
Immune Checkpoint Inhibitor-Induced Pancreatic Injury (ICI-PI) in Adult Cancer Patients: A Systematic Review and Meta-Analysis.成年癌症患者中免疫检查点抑制剂诱导的胰腺损伤（ICI-PI）：一项系统评价和荟萃分析
Cancers (Basel). 2025 Mar 24;17(7):1080. doi: 10.3390/cancers17071080.
4
Immune checkpoint inhibitor-related type 1 diabetes mellitus with closely monitored dynamics of glutamic acid decarboxylase antibody levels before and after disease onset.免疫检查点抑制剂相关的1型糖尿病，发病前后密切监测谷氨酸脱羧酶抗体水平的动态变化。
Diabetol Int. 2025 Feb 10;16(2):427-431. doi: 10.1007/s13340-025-00795-0. eCollection 2025 Apr.
5
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.9. 血糖治疗的药理学方法：2025年糖尿病护理标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S181-S206. doi: 10.2337/dc25-S009.
6
Case report: A case of sintilimab-induced recurrent diabetic ketoacidosis and thyroid dysfunction in a patient with advanced cervical carcinoma.病例报告：晚期宫颈癌患者使用信迪利单抗后复发糖尿病酮症酸中毒和甲状腺功能障碍。
Front Immunol. 2024 Oct 10;15:1405856. doi: 10.3389/fimmu.2024.1405856. eCollection 2024.
7
Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature.治疗中断后很久才发生的免疫检查点抑制剂相关1型糖尿病：一例报告及文献综述
Diabetol Int. 2024 Apr 18;15(3):605-610. doi: 10.1007/s13340-024-00719-4. eCollection 2024 Jul.
8
Pregnancy and delivery in an advanced cancer survivor with immune checkpoint inhibitor-induced type 1 diabetes: a case report.免疫检查点抑制剂诱导 1 型糖尿病的晚期癌症幸存者的妊娠和分娩：病例报告。
Endocrine. 2024 Aug;85(2):593-597. doi: 10.1007/s12020-024-03780-w. Epub 2024 Mar 19.
9
Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria.在不同临床场景中诊断检查点抑制剂诱导的糖尿病：更新诊断标准的实际应用
Diseases. 2024 Feb 14;12(2):40. doi: 10.3390/diseases12020040.
10
Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus.胰腺体积的明显变化而非胰腺自身抗体阳性：对免疫检查点抑制剂诱发糖尿病的见解。
Diabetol Metab Syndr. 2024 Jan 23;16(1):26. doi: 10.1186/s13098-024-01263-6.
Zotero 插件